Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma - Busse, William W.; Katial, Rohit; Gossage, David; Sari, Suha; Wang, Bing; Kolbeck, Roland; Coyle, Anthony J.; Koike, Masamichi; Spitalny, George L.; Kiener, Peter A.; Geba, Gregory P.; Molfino, Nestor A. (Journal of allergy and clinical immunology, 2010)
Keywords: Adolescent; Adult; Allergy and Immunology; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - pharmacokinetics; antibody-dependent cell-mediated cytotoxicity; Apoptosis - drug effects; Apoptosis - immunology; Asthma; Asthma - immunology; Asthma - pathology; Asthma - physiopathology; Asthma - therapy; Biological and medical sciences; C-Reactive Protein - metabolism; Cell Count; Chronic obstructive pulmonary disease, asthma; Eosinophil Cationic Protein - metabolism; eosinophils; Eosinophils - drug effects; Eosinophils - immunology; Eosinophils - metabolism; Eosinophils - pathology; Female; Follow-Up Studies; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Humans; IL-5; IL-5 receptor; Immunopathology; Immunotherapy; Interleukin-5 Receptor alpha Subunit - immunology; Interleukin-6 - metabolism; Lymphopenia - etiology; Male; Medical sciences; Middle Aged; monoclonal antibody; Pneumology; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - pharmacokinetics; Respiratory Function Tests; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; CRP; FENO; IL-5R; AE; CPKMB; antibody-dependent cell-mediated cytotoxicity; eosinophils; IL-5; AHR; Asthma; IL-5 receptor; PB; ECP; WBC; monoclonal antibody; JAK2; ADCC; CPK; C-reactive protein; Fractional exhaled nitric oxide; Creatine phosphokinase; Janus Activating Kinase 2; Peripheral blood; Creatine phosphokinase, muscle and brain; Adverse event; Airway hyperresponsiveness; FE NO; Eosinophil cationic protein; White blood cell; Human; Lung disease; Immunopathology; Respiratory disease; Toxicity; Cytokine; Granulocyte; Monoclonal antibody; Biological activity; Eosinophil; Immunology; Interleukin 5; Treatment; Antibody-dependent cell cytotoxicity; Phase I trial; Bronchus disease; Obstructive pulmonary disease; Pharmacokinetics; Biological receptor